Upregulation of microRNA-32 is associated with tumorigenesis and poor prognosis in patients with hepatocellular carcinoma

Yang,Huiqiong; Li,Yusheng; Zhong,Xiaoming; Luo,Pei; Luo,Ping; Sun,Ran; Xie,Ruting; Fu,Da; Ma,Yushui; Cong,Xianling; Li,Wenping

doi:10.3892/ol.2018.7879

Upregulation of microRNA-32 is associated with tumorigenesis and poor prognosis in patients with hepatocellular carcinoma

Authors:
- Huiqiong Yang
- Yusheng Li
- Xiaoming Zhong
- Pei Luo
- Ping Luo
- Ran Sun
- Ruting Xie
- Da Fu
- Yushui Ma
- Xianling Cong
- Wenping Li
View Affiliations

Affiliations: Department of Nuclear Medicine and Pathology, Shanghai 10th People's Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China, Department of Orthopedics, Xiangya Hospital, Central‑South University, Changsha, Hunan 410008, P.R. China, Department of Radiology, Jiangxi Provincial Tumor Hospital, Nanchang, Jiangxi 330029, P.R. China, Veterinary Faculty, College of Veterinary Medicine, Hunan Agricultural University, Changsha, Hunan 410128, P.R. China, Department of Breast Cancer, Nanchang Third Hospital, Nanchang, Jiangxi 330002, P.R. China, Tissue Bank, China‑Japan Union Hospital, Jilin University, Changchun, Jilin 130033, P.R. China
Published online on: January 26, 2018 https://doi.org/10.3892/ol.2018.7879
Pages: 4097-4104
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNA-32 (miR-32) is associated with tumor progression and poor prognosis in certain malignant tumors. However, the function and clinical relevance of miR‑32 in human hepatocellular carcinoma (HCC) has not yet been elucidated. The present study aimed to investigate the expression and prognostic value of miR‑32 from liver samples in patients with HCC. The expression of miR‑32 was analyzed in HCC and healthy tissues using Gene Expression Omnibus datasets. Reverse transcription‑quantitative polymerase chain reaction was used to analyze the levels of miR‑32 mRNA in 154 HCC liver samples, 33 of which were paired with adjacent non‑tumor tissues. The overall survival (OS) rate in patients with HCC was evaluated using Kaplan‑Meier survival analysis, and the factors that may affect the prognosis and survival of patients with HCC were analyzed using univariate (log‑rank test) and multivariate Cox proportional hazard models. The present results demonstrated that miR‑32 expression levels were significantly upregulated in HCC liver biopsies compared with normal tissues (P<0.05). miR‑32 expression was significantly associated with the number of foci and tumor diameter (P<0.05). In addition, Kaplan‑Meier analysis revealed that patients with low miR‑32 expression had longer OS and disease‑free survival compared with those with high miR‑32 expression (P<0.01). Altogether, to the best our knowledge, the present study is the first study to indicate the association between increased miR‑32 expression with HCC progression and poor prognosis in patients. This suggests that miR‑32 may have potential prognostic value and may be used as a tumor biomarker for the diagnosis of patients with HCC.

View Figures

View References

1	Wang Y, Ma Y, Fang Y, Wu S, Liu L, Fu D and Shen X: Regulatory T cell: A protection for tumor cells. J Cell Mol Med. 16:425–436. 2012. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. Ca Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
3	Forner A, Llovet JM and Bruix J: Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
4	Fang Y, Fu D, Tang WQ, Cai Y, Ma D, Wang HJ, Xue RY, Liu TT, Huang XW, Dong L, et al: Ubiquitin C-terminal hydrolase 37, a novel predictor for hepatocellular carcinoma recurrence, promotes cell migration and invasion via interacting and deubiquitinating PRP19. Biochim Biophys Acta. 1833:559–572. 2013. View Article : Google Scholar : PubMed/NCBI
5	Chen YJ, Ma YS, Fang Y, Wang Y, Fu D and Shen XZ: Power and promise of ubiquitin carboxyl-terminal hydrolase 37 as a target of cancer therapy. Asian Pac J Cancer Prev. 14:2173–2179. 2013. View Article : Google Scholar : PubMed/NCBI
6	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
7	Liu LL, Fu D, Ma Y and Shen XZ: The power and the promise of liver cancer stem cell markers. Stem Cells Dev. 20:2023–2030. 2011. View Article : Google Scholar : PubMed/NCBI
8	Hou LK, Ma YS, Han Y, Lu GX, Luo P, Chang ZY, Xie RT, Yang HQ, Chai L, Cai MX, et al: Association of microRNA-33a molecular signature with non-small cell lung cancer diagnosis and prognosis after chemotherapy. PLoS One. 12:e01704312017. View Article : Google Scholar : PubMed/NCBI
9	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
10	Cho WC: OncomiRs: The discovery and progress of microRNAs in cancers. Mol Cancer. 6:602007. View Article : Google Scholar : PubMed/NCBI
11	Jay C, Nemunaitis J, Chen P, Fulgham P and Tong AW: miRNA profiling for diagnosis and prognosis of human cancer. DNA Cell Biol. 26:293–300. 1007. View Article : Google Scholar
12	Wu W, Yang J, Feng X, Wang H, Ye S, Yang P, Tan W, Wei G and Zhou Y: MicroRNA-32 (miR-32) regulates phosphatase and tensin homologue (PTEN) expression and promotes growth, migration, and invasion in colorectal carcinoma cells. Mol Cancer. 12:302013. View Article : Google Scholar : PubMed/NCBI
13	Fang Y, Fu D and Shen XZ: The potential role of ubiquitin C-terminal hydrolases in oncogenesis. Biochim Biophys Acta. 1806:1–6. 2010.PubMed/NCBI
14	Jalava SE, Urbanucci A, Latonen L, Waltering KK, Sahu B, Jänne OA, Seppälä J, Lähdesmäki H, Tammela TL and Visakorpi T: Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer. Oncogene. 31:4460–4471. 2012. View Article : Google Scholar : PubMed/NCBI
15	Bai Y, Wang YL, Yao WJ, Guo L, Xi HF, Li SY and Zhao BS: Expression of miR-32 in human non-small cell lung cancer and its correlation with tumor progression and patient survival. Int J Clin Exp Pathol. 8:824–829. 2015.PubMed/NCBI
16	Xu JQ, Zhang WB, Wan R and Yang YQ: MicroRNA-32 inhibits osteosarcoma cell proliferation and invasion by targeting Sox9. Tumor Biol. 35:9847–953. 2014. View Article : Google Scholar
17	Zhang J, Kuai X, Song M, Chen X, Yu Z, Zhang H and Mao Z: microRNA32 inhibits the proliferation and invasion of the SGC-7901 gastric cancer cell line in vitro. Oncol Lett. 7:270–274. 2014. View Article : Google Scholar : PubMed/NCBI
18	Zhang D, Ni Z and Xu X: Decreased microRNA-32 in oral squamous cell carcinoma. Med Sci Monit. 20:2527–2535. 2014.PubMed/NCBI
19	Yan SY, Chen MM, Li GM, Wang YQ and Fan JG: miR-32 induces cell proliferation, migration, and invasion in hepatocellular carcinoma by targeting PTEN. Tumor Biol. 36:4747–4755. 2015. View Article : Google Scholar
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Fang Y, Mu J, Ma Y, Ma D, Fu D and Shen X: The interaction between ubiquitin C-terminal hydrolase 37 and glucose-regulated protein 78 in hepatocellular carcinoma. Mol Cell Biochem. 359:59–66. 2012. View Article : Google Scholar : PubMed/NCBI
22	Ma YS, Wu TM, Lv ZW, Lu GX, Cong XL, Xie RT, Yang HQ, Chang ZY, Sun R, Chai L, et al: High expression of miR-105-1 positively correlates with clinical prognosis of hepatocellular carcinoma by targeting oncogene NCOA1. Oncotarget. 8:11896–11905. 2017.PubMed/NCBI
23	Wu SD, Ma YS, Fang Y, Liu LL, Fu D and Shen XZ: Role of the microenvironment in hepatocellular carcinoma development and progression. Cancer Treat Rev. 38:218–225. 2012. View Article : Google Scholar : PubMed/NCBI
24	Ge S and Huang D: Systemic therapies for hepatocellular carcinoma. Drug Discov Ther. 9:352–362. 2015. View Article : Google Scholar : PubMed/NCBI
25	Bartels CL and Tsongalis GJ: MicroRNAs: Novel biomarkers for human cancer. Ann Biol Clin (Paris). 68:263–272. 2010.(In French). PubMed/NCBI
26	Ma Y, Hou L, Yu F, Lu G, Qin S, Xie R, Yang H, Wu T, Luo P, Chai L, et al: Incidence and physiological mechanism of carboplatin-induced electrolyte abnormality among patients with non-small cell lung cancer. Oncotarget. 8:18417–18423. 2017.PubMed/NCBI
27	Li LM, Hu ZB, Zhou ZX, Chen X, Liu FY, Zhang JF, Shen HB, Zhang CY and Zen K: Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res. 70:9798–9807. 2010. View Article : Google Scholar : PubMed/NCBI
28	Sukata T, Sumida K, Kushida M, Ogata K, Miyata K, Yabushita S and Uwagawa S: Circulating microRNAs, possible indicators of progress of rat hepatocarcinogenesis from early stages. Toxicol Lett. 200:46–52. 2011. View Article : Google Scholar : PubMed/NCBI
29	Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B, Mazzaferro V, Lowe SW, Croce CM and Dejean A: miR-221 overexpression contributes to liver tumorigebesis. Proc Natl Acad Sci USA. 107:pp. 264–269. 2010; View Article : Google Scholar : PubMed/NCBI
30	Wang X, Zhu Y, Ma Y, Wang J, Zhang F, Xia Q and Fu D: The role of cancer stem cells in cancer metastasis: New perspective and progress. Cancer Epidemiol. 37:60–63. 2013. View Article : Google Scholar : PubMed/NCBI
31	Zhu D, Chen H, Yang X, Chen W, Wang L, Xu J and Yu L: miR-32 functions as a tumor suppressor and directly targets SOX9 in human non-small cell lung cancer. Onco Targets Ther. 8:1773–1783. 2015. View Article : Google Scholar : PubMed/NCBI
32	Wu W, Yang P, Feng X, Wang H, Qiu Y, Tian T, He Y, Yu C, Yang J, Ye S and Zhou Y: The relationship between and clinical significance of MicroRNA-32 and phosphatase and tensin homologue expression in colorectal cancer. Genes Chromosomes Cancer. 52:1133–1140. 2013. View Article : Google Scholar : PubMed/NCBI
33	Wang H, Xu T, Jiang Y, Xu H, Yan Y, Fu D and Chen J: The challenges and the promise of molecular targeted therapy in malignant gliomas. Neoplasia. 17:239–255. 2015. View Article : Google Scholar : PubMed/NCBI
34	Sato F, Hatano E, Kitamura K, Myomoto A, Fujiwara T, Takizawa S, Tsuchiya S, Tsujimoto G, Uemoto S and Shimizu K: MicroRNA profile predicts recurrence after resection in patients with hepatocellular carcinoma within the Milan Criteria. PLoS One. 6:e164352011. View Article : Google Scholar : PubMed/NCBI
35	Burchard J, Zhang C, Liu AM, Poon RT, Lee NP, Wong KF, Sham PC, Lam BY, Ferguson MD, Tokiwa G, et al: microRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma. Mol Syst Biol. 6:4022010. View Article : Google Scholar : PubMed/NCBI